ARCHIVES

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

This article is from The Cancer Letter archive.

Vol. 31 No. 7 | July 25, 2008

Download PDF Visit The Full Archive

Related Articles

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002

ASCO Says FDA Plan For ESA Management Will Burden Oncologists

March 5, 2010

Project Expands Group Studies To Community Oncologists.

March 10, 2000

DCPC Board Oks Program To Encourage Produce Consumption

October 25, 1991

As Bristol’s Final Defenses Fall, IVAX Prepares Launch Of Generic Paclitaxel.

October 20, 2000

Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds

May 27, 2005